Vosoritide (Voxzogo)

FDA-approved product existsGrowth SignalingGH axis & hormones

Awaiting review, BioHarmony verdict

Not yet scored. Queued for review; until then rely on the status and sources below.

What is Vosoritide (Voxzogo)?

FDA-approved vosoritide is marketed as Voxzogo to increase linear growth in pediatric patients with achondroplasia and open epiphyses.

Saved on this device only.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

Approved labelVOXZOGO prescribing information for pediatric achondroplasia with open epiphyses
PopulationPediatric patients covered by the approved VOXZOGO indication
DoseWeight-based once-daily dosing from 0.096 mg to 0.8 mg according to the prescribing-information table
RouteSubcutaneous injection
FrequencyOnce daily
DurationUntil confirmation of no further growth potential, with weight and growth reassessed every 3 to 6 months
PreparationUse the entire supplied diluent syringe: 0.5 mL for the 0.4 mg vial, 0.7 mL for the 0.56 mg vial, or 0.6 mL for the 1.2 mg vial. Gently swirl; do not shake. Use within 3 hours and discard unused portion.
Source: Dosage and Administration sections 2.2-2.4; Dosage Forms and Strengths section 3

Working with a vial? The reconstitution calculator covers mixing math, not dosing advice.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalFDA-approved product exists
CompoundingFDA-approved product exists; compounded copies are not FDA approved

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.